Articles

SPECIAL REPORT: Stock-based pay builds wealth for Indiana execs

IBJ's annual review of proxy statements for Indiana public companies found senior executives' median compensation rose 14 percent in 2011. But that analysis uses the fair market value of stock and options awards on the date they were granted. If a company's stock price surges, executives can make out far better. (with searchable database)

Read More

Activists plan to protest WellPoint political giving at meeting

A mix of union groups, activist investors and single-payer advocates will call for increased disclosure from WellPoint, and some investment funds will vote against WellPoint board members who they say have failed to exercise proper oversight of WellPoint’s political spending.

Read More

Lilly: Forget Alzheimer’s; think diabetes

For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.

Read More

Six Hoosier firms among country’s 500 largest

Indianapolis-based WellPoint Inc. topped the list of Indiana companies, ranking 45th. Locally, Eli Lilly and Co. and BrightPoint Inc. also made Fortune magazine's latest annual ranking of the 500 largest corporations based on revenue.

Read More

Allison earnings rise on surging sales

Allison Transmission Holdings Inc. saw profits rise 57 percent, to $58 million, in the first quarter, the Indianapolis-based manufacturer announced Monday. The earnings announcement was Allison’s first since it went public in March.

Read More

Simon CEO lands $137 million in compensation

David Simon must remain CEO of Indianapolis-based Simon Property Group for at least six years to see any of the $120 million in special stock awards the company’s board of directors awarded him last year, and must stay on eight years to reap the full amount.

Read More

New Lilly drug has small sales potential

Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.

Read More